Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Barcelona, Spain – 28 Aug 2017: PCSK9 inhibition could ameliorate atherosclerosis and thus cardiovascular disease by immune mechanisms that are unrelated to lowering of low-density lipoprotein (LDL) cholesterol, according to research presented today at ESC Congress.1T cells and dendritic cells are common in atherosclerotic plaques. Atherosclerosis is a chronic inflammatory process in which activation of these immune cells may play a major role in the development of cardiovascular disease.Researchers at the Karolinska Institute in Stockholm, Sweden, developed an experimental system to directly study how these immune cells from human atherosclerotic plaques are activated in order to discover mechanisms and potential therapies.Specifically, they examined proprotein convertase subtilisin kexin 9 (PCSK9), which is known to target the LDL receptor for degradation, resulting in increased LDL levels. Knowledge of this mechanism has led to the development of PCSK9 inhibitors, which lower LDL cholesterol.In this study, researchers investigated the immune effects of PCSK9 on the induction of dendritic cell maturation and T cell activation by oxidised LDL.T cells were isolated from the carotid arteries of patients with atherosclerotic plaques who were undergoing carotid endarterectomy to clear the blocked arteries. T cells were also obtained from the peripheral blood of healthy individuals. Human peripheral blood monocytes were differentiated into dendritic cells.The dendritic cells were pretreated with oxidised LDL and then co-cultured with T cells from atherosclerotic plaques and from blood. The researchers studied the effects of PCSK9 and its inhibition on the T cells and dendritic cells.They found that oxidised LDL promoted the maturation of dendritic cells. These dendritic cells then mediated the activation of T cells into T helper cells. Oxidised LDL also induced PCSK9. PCSK9 inhibition (by silencing the gene) reversed the effects of oxidised LDL on dendritic cells and T cells. Dendritic cell maturation was repressed, as was the activation of T cells.Lead author Prof Johan Frostegård, professor of medicine and senior consultant at the Karolinska Institute, said: “We demonstrated for the first time that PCSK9 inhibition reversed the effects of oxidised LDL on immune activation. This changed a pro-inflammatory profile into an anti-inflammatory state that is potentially anti-atherosclerotic.”Prof Frostegård continued: “Our study suggests that the benefits of PCSK9 inhibition extend beyond lowering LDL cholesterol. Here we show that PCSK9 inhibition has a novel immunological role in the maturation and activation of dendritic cells and T cells by oxidised LDL, a central player in atherosclerosis. This creates an anti-inflammatory state which may directly influence atherosclerosis and cardiovascular disease, independent of LDL-lowering.”“Interestingly, statins also have anti-inflammatory and immune modulatory roles in addition to lipid lowering, although these are not exerted through the same mechanisms as those observed with PCSK9 inhibition,” he added.ENDS
Sources of funding: The Swedish Heart Lung Foundation, the Swedish Research Council, the Stockholm County (ALF), the King Gustav V 80th Birthday Fund, Swedish Association against Rheumatism, Vinnova, AFA, Torsten Söderberg´s Foundation.
References and notes
1The abstract “PCSK9 plays a novel immunological role in Oxidized LDL-induced dendritic cell maturation and T cell activation from human blood and atherosclerotic plaque” will be presented during:
ESC Press OfficeFor more information, please contact the ESC Press Office: email@example.com.For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856The press conference timetable is available here.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. About the European Society of CardiologyThe European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.About ESC Congress 2017ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at firstname.lastname@example.org.This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved